History
Lapatinib in the Treatment of HER2-Positive Breast Cancer Patients
Date of publication: May 31, 2021 Evidence Summary: https://drive.google.com/file/d/1VH5tkZyZr9sGWERXk8eXOyIQno456ixT/view Advisory on non-inclusion in PNF: https://drive.google.com/file/d/19PKRWWZ70bKUJBBuKyXnUjCtK01tzEgL/view (Proponents may submit appeals to hta@doh.gov.ph until 14 June 2021.) HTAC Recommendation Review:
Potassium Citrate [1620 mg (15 mEq)] Tablet
SOH approves the HTAC recommendation on the minor inclusion of an additional dosage strength of potassium citrate [1620 mg (15mEq)] tablet for severe hypocitraturia and recurrent kidney stones in the Philippine National Formulary (PNF) The Secretary of Health (SOH) approved the Health Technology Assessment Council (HTAC) recommendation on the minor inclusion of an additional dosage continue reading : Potassium Citrate [1620 mg (15 mEq)] Tablet
Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)
The Secretary of Health (SOH) approved the HTAC recommendation on April 21 to finance a fourth dose of COVID-19 Vaccines AstraZeneca, CoronaVac, Moderna, Pfizer-BioNTech, and Sinopharm among the immunocompromised population (ICPs) ages 18 years old and above given at least 3 months after the third dose, and include these vaccines in the Philippine National Deployment and Vaccination Plan for COVID-19 (NDVP). While continue reading : Fourth Dose of COVID-19 Vaccines Among the Immunocompromised Population (ICPs)
Use of Self-Administered Antigen Testing for COVID-19
Date of publication: 07 April 2022 Signed by the Secretary of Health: 28 June 2022 Objectives: HTA Council Recommendation: Evidence Summary: